menu
    • menu
    [{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PY314","moa":"TREM2","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"PY265","moa":"MARCO receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Pionyr Immunotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Financing","leadProduct":"IK-930","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Pionyr Immunotherapeutics \/ Pionyr Immunotherapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Pionyr Immunotherapeutics"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Ikena Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Acquisition","leadProduct":"PY314","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Pionyr Immunotherapeutics \/ Ikena Oncology","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Ikena Oncology"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Acquisition","leadProduct":"PY159","moa":"||TREM1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Pionyr Immunotherapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"PY159","moa":"||TREM1","graph1":"Oncology","graph2":"Phase I","graph3":"Pionyr Immunotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Pionyr Immunotherapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Pionyr Immunotherapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Pionyr Immunotherapeutics

    Menu

    Pionyr Immunotherapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IK-930

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Ikena Oncology

                            Deal Size : $43.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction, New Capital will Expand Ikena's Pi...

                            Details : The net proceeds will be used to expand and accelerate Ikena’s targeted oncology programs, including both IK-930, a TEAD1 selective Hippo pathway inhibitor, and IK-595, a MEK-RAF complexing inhibitor.

                            Product Name : IK-930

                            Product Type : Small molecule

                            Upfront Cash : $43.0 million

                            August 07, 2023

                            Lead Product(s) : IK-930

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Ikena Oncology

                            Deal Size : $43.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY314,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Ikena Oncology

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

                            Details : Through the acquisition, Ikena gains all of Pionyr’s assets including, PY314 and PY159, targeting TREM2 and TREM1 respectively, which are designed to selectively deplete and in some cases reprogram certain tumor-associated macrophages responsible for i...

                            Product Name : PY314

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 07, 2023

                            Lead Product(s) : PY314,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Ikena Oncology

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement

                            Details : Gilead has waived its exclusive option to acquire Pionyr. Pionyr will be responsible for the development of its pipeline, including PY159, PY314 and PY265. PY159 targeting TREM1 and PY314 targeting TREM2 will continue to advance in Phase 1b studies in mu...

                            Product Name : PY159

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            March 23, 2023

                            Lead Product(s) : PY159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Gilead Sciences

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY265,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pionyr Immunotherapeutics’ MARCO-targeting Antibody Program, PY265, for Treatment of Solid Tumors Featured a...

                            Details : PY265 is a monoclonal antibody targeting macrophage receptor with a collagenous structure (MARCO), a protein expressed on the surfaces of immuno-suppressive myeloid cells including tumor-associated macrophages (TAMs) and monocytic myeloid-derived suppres...

                            Product Name : PY265

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 07, 2022

                            Lead Product(s) : PY265,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tu...

                            Details : First in human clinical experience administering PY159 both alone and in combination with pembrolizumab including identification of target archival tumor specimens from participating patients.

                            Product Name : PY159

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            June 16, 2022

                            Lead Product(s) : PY159,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed

                            Pionyr Immunotherapeutics

                            U.S.A arrow
                            The Generic Rx Session
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PY314,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Pionyr Immunotherapeutics’ Phase 1a Study of TREM2-targeting Antibody PY314 for the Treatment of Solid Tumor...

                            Details : PY314 was well tolerated over a range of doses both as a single agent and in combination with checkpoint inhibitor pembrolizumab at its label approved dose.

                            Product Name : PY314

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 26, 2022

                            Lead Product(s) : PY314,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth